Inhibikase appoints Gisele Dion to Board, replacing retiring Elizabeth O'Farrell

Inhibikase Therapeutics, Inc.

Elizabeth O'Farrell retired from the Board effective Sep 1, 2022; departure not due to any disagreement.
Gisele Dion appointed as Class III director effective Sep 1, 2022.
Dion receives $65k annual cash and a 60,000-share option grant (50% vest each of first two anniversaries).
Dion previously SVP & CAO at Takeda, CAO at Shire, and board member at Cytek Biosciences.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gisele Dion

Director

IKT · Inhibikase Therapeutics, Inc.

Effective: 2022-09-01
Filed: September 1, 2022, 7:59 PM ET

Following Ms. O’Farrell’s resignation, on September 1, 2022, the Board appointed Gisele Dion to serve as a Class III member of the Board.

Departed

Elizabeth O’Farrell

Director

IKT · Inhibikase Therapeutics, Inc.

Effective: 2022-09-01
Successor: Gisele Dion
Filed: September 1, 2022, 7:59 PM ET

On September 1, 2022, Elizabeth O’Farrell provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of her intention to retire from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gisele Dion was appointed as Director at Inhibikase Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Following Ms. O’Farrell’s resignation, on September 1, 2022, the Board appointed Gisele Dion to serve as a Class III member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Elizabeth O’Farrell retired as Director at Inhibikase Therapeutics, Inc..

Action: retired
Role: Director

Exact text from the filing

On September 1, 2022, Elizabeth O’Farrell provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of her intention to retire from the Board, effective immediately.

View on SEC.gov

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-236658

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.